Novo Nordisk announced on Thursday that a key European Medicines Agency committee has backed a label update for weight-loss ...

EU regulator supports a label expansion of Novo Nordisk’s diabetes drug to reflect its potential to lower the risk of ...

The European Medicines Agency (EMA) will allow Novo Nordisk to add risk reduction for events related to kidney disease to the ...

A recent New York Times story described a new fad: "microdosing" GLP-1 anti-obesity drugs like semaglutide (Ozempic, Wegovy) ...

Biotech leader says additional research into existing medications, drug classes, and mechanisms of action can bring forth ...

Doctors might be slow to admit it, but Ozempic and other GLP-1 drugs are making dieting and exercise obsolete.

A new analysis estimates that losing as little as 5% weight can lead to substantial savings in health care costs elsewhere.

They’ve been heralded as the magic drugs that treat obesity when diet and exercise have failed. But Ozempic and Wegovy – and ...

Novo Nordisk's Lotte Bjerre Knudsen says her determination is a key part of the success, but she also stays humble.

Shares of Hershey Co. booked a double-digit percentage gain on Monday after Bloomberg reported that Oreo maker Mondelez ...

“We know in smaller studies that when women with PCOS take semaglutide, it increases the regularity of the menstrual cycle, ...

MIT engineers have revealed a new gastric balloon design that can inflate on demand to make you feel full before meals.